Cart
sales@molnova.com
Cav 2.2 blocker 1
CAS No. 1567335-29-8
Cav 2.2 blocker 1( —— )
Catalog No. M23678 CAS No. 1567335-29-8
Cav 2.2 blocker 1 is an N-type calcium channel (Cav 2.2; IC50: 1 nM) blocker for the treatment of pain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 113 | In Stock |
|
| 5MG | 107 | In Stock |
|
| 10MG | 183 | In Stock |
|
| 25MG | 340 | In Stock |
|
| 50MG | 510 | In Stock |
|
| 100MG | 764 | In Stock |
|
| 200MG | 1004 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCav 2.2 blocker 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCav 2.2 blocker 1 is an N-type calcium channel (Cav 2.2; IC50: 1 nM) blocker for the treatment of pain.
-
DescriptionCav 2.2 blocker 1 is an N-type calcium channel (Cav 2.2; IC50: 1 nM) blocker for the treatment of pain.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCav 2.2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1567335-29-8
-
Formula Weight424.96
-
Molecular FormulaC25H29ClN2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:20 mg/mL (47.07 mM; Need ultrasonic)
-
SMILESCC1(C)CC(C2=NN(C3=CC=CC=C3OC)C(C4=CC=C(Cl)C=C4)=C2)CC(C)(C)O1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wall MJ, et al. Discovery and optimization of a novel series of pyrazolyltetrahydropyran N-type calcium channel (Cav 2.2) blockers for the treatment of pain. Bioorg Med Chem Lett. 2018 Dec 15;28(23-24):3780-3783.
molnova catalog
related products
-
Ziconotide
Ziconotide is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus, a cone snail, it is the synthetic form of an ω-conotoxin peptide.
-
Trimethadione
Trimethadione is an oxazolidinedione anticonvulsant; commonly used to treat epileptic conditions.
-
O-1602
O-1602 is a novel GPR55 agonist, an atypical cannabinoid associated with the central nervous system and obesity, and is a candidate compound for the treatment of cystitis.
